Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 107 clinical trials
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

lack of efficacy) 2. Adding bortezomid during the induction: The very early or early bone marrow relapse has low remission rate. Previous case studies showed that Bortezomib, a proteasome

  • 0 views
  • 23 Feb, 2022
  • 1 location
A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma

or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

bortezomib
monoclonal antibodies
dexamethasone
immunoglobulin
immunomodulatory imide drug
  • 0 views
  • 22 Apr, 2022
  • 15 locations
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)

myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

bortezomib
immunoglobulins
platelet count
serum calcium
neutrophil count
  • 3 views
  • 26 Feb, 2022
  • 3 locations
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

induction regimens to lenalidomide-based associations, which is now the backbone of most treatment for NTE patients. Even though the latest melphalan, bortezomib and prednisone (MPV) association was

velcade
bortezomib
dexamethasone
prednisone
measurable disease
  • 0 views
  • 10 May, 2022
  • 1 location
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as

monoclonal antibodies
bortezomib
cyclophosphamide
prednisone
cancer
  • 0 views
  • 09 Apr, 2022
  • 1 location
REST - Replacing Steroids in the Transplant Ineligble (REST)

Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the study. All participants will receive isatuximab in combination with bortezomib, lenalidomide and minimal

bortezomib
dexamethasone
measurable disease
platelet count
bone marrow procedure
  • 0 views
  • 03 May, 2022
  • 3 locations
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

, dexamethasone and bortezomib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

bortezomib
tyrosine
glomerular filtration rate
etoposide
clofarabine
  • 27 views
  • 04 Jun, 2022
  • 1 location
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: immediate daratumumab + VCd

daratumumab
dexamethasone
cyclophosphamide
amyloid deposition
  • 5 views
  • 12 Jul, 2022
  • 4 locations
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

This is a phase Ib study to assess the safety, tolerability, preliminary efficacy, and renal response of isatuximab, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients

hypercalcemia
dexamethasone
velcade
bortezomib
bone marrow procedure
  • 0 views
  • 27 Apr, 2022
  • 1 location
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib

daratumumab
dexamethasone
high dose chemotherapy
bortezomib
chemotherapy regimen
  • 1 views
  • 26 Jul, 2022
  • 3 locations